Stocks · News reference

Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis

Jun 25, 2026, 11:27 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 9:21 PMBenzinga Newsdesk
Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units
SERES THERAPEUTICS, INC.$300,000,000Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more
MCRB
BenzingaAug 5, 2026, 11:29 AMBenzinga Newsdesk
Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of $(2.27) per share
MCRB
SEC EDGARAug 5, 2026, 11:05 AMSEC EDGAR
8-K filing — Seres Therapeutics, Inc. (MCRB)
Filed: 2026-08-05 AccNo: 0001193125-26-333820 Size: 241 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
MCRB
BenzingaJul 8, 2026, 5:07 PMVandana Singh
Seres Therapeutics Posts Early Data for Cancer Therapy Complication
Seres Therapeutics reported early SER-155 data, with 80% of patients achieving steroid-free clinical response by Day 15.
MCRB